SS
SPRO icon

SBI Securities’s Spero Therapeutics SPRO Stock Holding History

SBI Securities’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21 Hold
9
– – ﹤0.01% 3758
2025
Q4 		$21 Sell
9
-1
-10% -$2 ﹤0.01% 3770
2025
Q3 		$19 Sell
10
-52
-84% -$114 ﹤0.01% 3930
2025
Q2 		$180 Buy
62
+2
+3% +$3 ﹤0.01% 3351
2025
Q1 		$43 Sell
60
-153
-72% -$129 ﹤0.01% 3688
2024
Q4 		$219 Buy
+213
New +$253 ﹤0.01% 3205

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SBI Securities's SPRO Position: Q1 2026 in Review

SBI Securities held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 9 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

SBI Securities first reported a position in SPRO in Q4 2024 and has held it in 6 quarters since. The position peaked at $219 in Q4 2024. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • SBI Securities held 9 shares of Spero Therapeutics worth $21 as of Q1 2026.
  • SBI Securities left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3758 holding.
  • SBI Securities first reported a position in Spero Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Spero Therapeutics position peaked at $219 in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.